Merck Licenses SciBrunch's KRAS G12D Inhibitor
Merck enters into exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor.
Merck SPR2015 License Agreement | 29/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy